MATTHEW JAMES PIANKO, M.D.

Plain English
This study looked at the use of a treatment called linvoseltamab in patients with multiple myeloma that was hard to treat or had returned after previous therapy. Over a follow-up period of about 21 months involving 117 patients, 71% showed improvement in their condition, with 52% experiencing complete recovery. The findings indicate that this treatment is effective and safe, giving hope for better outcomes in these patients. Who this helps: This research benefits patients with relapsed/refractory multiple myeloma and their doctors.

Plain English
Researchers tested thousands of existing drugs to find new ways to kill multiple myeloma cancer cells, and discovered that a drug called RTA408 works by blocking a cellular cleanup system that myeloma cells depend on to survive. When RTA408 shuts down this cleanup system, cancer cells die through a specific mechanism involving the cell's outer membrane, and it kills even myeloma cells that have become resistant to current treatments. This finding could lead to a new treatment option for multiple myeloma patients who no longer respond to standard drugs.

Plain English
This study looked at how frailty, a condition that makes older adults more vulnerable to stress and health challenges, affects treatment outcomes and quality of life for patients with multiple myeloma, a type of blood cancer. The findings showed that frail individuals had worse treatment results and overall quality of life, highlighting the need for tailored treatment approaches. By considering frailty in treatment plans, doctors can better help older patients with myeloma manage their health and improve their quality of life. Who this helps: Older patients with multiple myeloma.

Plain English
This study examined factors that influence whether newly diagnosed multiple myeloma patients, who cannot undergo a transplant, are started on combination therapies involving either two (doublets) or three (triplets) medications. The researchers found that older and frail patients were more often given doublet therapy, while factors like being Black, living in urban areas, and having more complicated disease characteristics were linked to initiating triplet therapy. This matters because triplet therapies have been shown to be more effective than doublets, indicating there is a chance to improve treatment outcomes for older and frail patients. Who this helps: Patients with multiple myeloma and their doctors.

Plain English
This study looked at how well teclistamab works for patients with multiple myeloma who also have kidney problems, as about half of these patients are affected by renal impairment. It found that teclistamab could be safe and beneficial for those with mild to moderate renal impairment, even including patients on dialysis, as long as certain precautions are taken. This is important because it helps provide treatment options for a group of patients who often miss out on new therapies due to strict clinical trial rules. Who this helps: Patients with multiple myeloma and renal impairment.

Plain English
Researchers tested thousands of existing drugs to find one that could block a cellular cleanup system called ERAD, and discovered that a drug called omaveloxolone (RTA408) does this effectively. When they applied this drug to multiple myeloma cancer cells—including ones that resist other treatments—it triggered the cancer cells to self-destruct by activating their internal death signals. This matters because multiple myeloma is currently incurable, and omaveloxolone could become a new treatment option, either alone or combined with existing drugs.

Plain English
Researchers studied the safety and dosage of a drug called lenalidomide in patients with anti-myelin-associated glycoprotein neuropathy, a disease with no approved treatments. They discovered that although the maximum tolerated dose was 25 mg, a safer recommended dose is 15 mg, due to a high incidence of blood clotting issues known as venous thromboembolism (VTE) during the trial. The study showed no significant improvement in disability after a year, indicating that the risks of using lenalidomide may outweigh the benefits for these patients. Who this helps: This information helps patients with anti-MAG neuropathy and their doctors make informed decisions about treatment options.

Plain English
Researchers studied the use of a drug called teclistamab in four patients who had multiple myeloma and were on dialysis for kidney issues. They found that all four patients were able to tolerate the treatment well, with only one experiencing a mild reaction that was easily managed. This is important because it shows that teclistamab can be safely used in patients with tough conditions, paving the way for better treatment options for those who have both multiple myeloma and kidney problems. Who this helps: This helps patients with multiple myeloma who also have kidney issues.

Plain English
This study looked at a new treatment called linvoseltamab for patients with relapsed or refractory multiple myeloma, a type of blood cancer that hasn’t responded to other treatments. In 117 patients taking a higher dose of 200 mg, 71% showed improvement in their condition within 14 months, and half of them had a complete response. The treatment appears effective and has a manageable safety profile, with serious side effects like infections reported in around 74% of patients, but these typically lessened over time. Who this helps: This research benefits patients with multiple myeloma who have run out of treatment options.

Plain English
This study examined how well a drug called colesevelam works to treat diarrhea caused by lenalidomide in patients with multiple myeloma. Out of 25 patients treated for 12 weeks, 88% experienced an improvement in their diarrhea, with 68% completely resolving their symptoms. This finding is important because it means that colesevelam can effectively help patients manage a common and uncomfortable side effect of their cancer treatment without interfering with the effectiveness of lenalidomide. Who this helps: Patients with multiple myeloma experiencing diarrhea from lenalidomide treatment.

Plain English
This study looked at how well two experimental treatments, anti-TIGIT and anti-LAG3, work for people with myeloma when combined with two other drugs. They found that three out of six people did well with the anti-TIGIT treatment and two out of six with the anti-LAG3 treatment, with no severe side effects reported. These findings are important because they show that blocking these specific immune pathways can effectively help some myeloma patients, leading to better treatment options. Who this helps: This helps patients with myeloma looking for more effective treatment choices.

Plain English
This study looked at how a part of the immune system called C3d helps the body recognize and fight cancerous cells in mice with multiple myeloma, a type of blood cancer. The researchers found that C3d significantly reduced tumor size by 10 times over eight weeks and specifically aided the immune system in targeting malignant plasma cells while leaving normal cells mostly unharmed. This is important because it shows a new way that the immune system can be harnessed to treat cancer without damaging healthy cells. Who this helps: This helps patients with multiple myeloma and potentially other types of cancer.

Plain English
This study looked at how a protein called C3d helps the immune system identify and attack cancer cells while leaving healthy cells alone. In mice with multiple myeloma, researchers found that C3d boosts immune responses specifically against malignant plasma cells, leading to their elimination without harming normal cells. This targeted action is important because it shows a way to improve immune therapy against cancer with minimal side effects. Who this helps: This benefits cancer patients, particularly those with multiple myeloma.

Plain English
This study looked at the risk of bacterial infections in patients with newly diagnosed multiple myeloma who were treated with a combination of three medications: bortezomib, lenalidomide, and dexamethasone, between 2014 and 2020. Out of 144 patients, 21 (or 14.5%) developed a bacterial infection, with 8 of those (5.5%) classified as severe infections. The study found that factors like older age, a history of smoking, diabetes, recent antibiotic use, and certain genetic risks increased the chances of getting an infection. Who this helps: This information benefits patients and doctors by identifying those at higher risk for infections during treatment.

Plain English
This study looked at the effects of treatment on kidney health in 34 patients with monoclonal immunoglobulin deposition disease (MIDD), which often harms the kidneys. Most patients responded well to treatment, with 94% showing significant improvement, and 79% of those assessed met the criteria for a positive kidney response. The findings highlight that a unified approach to measuring kidney response is important for better patient care. Who this helps: This benefits patients with MIDD and their doctors by improving treatment strategies for kidney health.

Plain English
This study looked at older adults diagnosed with multiple myeloma, focusing on how their frailty—measured by their health and abilities—changed over time. Researchers found that at the start, 39% of the patients were considered moderately or severely frail, and within three years, 93% of these patients experienced a change in their frailty status—78% improved, while 72% got worse at some point. This matters because it shows that frailty is not a fixed state; assessing frailty regularly is crucial for better predicting patient outcomes. Who this helps: This helps patients and doctors manage the care of older adults with multiple myeloma more effectively.

Plain English
This study looked at how obesity affects the growth and survival of multiple myeloma (a type of blood cancer) cells. Researchers found that fat cells in the bone marrow can produce factors that reduce the activity of a protein called aryl hydrocarbon receptor (AhR) in multiple myeloma cells. They discovered that when AhR activity decreases, it leads to worse outcomes for patients, meaning that more significant cancer progression was observed in patients with lower AhR activity. Who this helps: This information benefits patients with multiple myeloma, as it could lead to better understanding and treatments for those affected by obesity and this cancer.

Plain English
This study examined how the microbes living in our bodies, particularly in the gut, affect people with multiple myeloma (a type of blood cancer) and those undergoing stem cell transplants. It found that patients with more diverse gut microbiota had better results after treatment, with improvements in survival and reduced risks of complications; specifically, those with greater gut microbe diversity had superior outcomes post-transplant. This matters because understanding these interactions can lead to better treatment strategies and outcomes for patients battling blood cancers. Who this helps: This research benefits patients with multiple myeloma and those receiving stem cell transplants.

Plain English
This study looked at how diet affects a special biological marker in multiple myeloma patients that can indicate better treatment outcomes. Researchers found that patients with higher levels of butyrate— a substance produced by certain gut bacteria— had a lower risk of remaining ill after treatment, with significant associations at the three-month mark (P values of 0.037 for butyrate levels and 0.025 for butyrate-producing bacteria). Eating healthier plant-based foods also played a role, with seafood and plant proteins linked to better butyrate production. Who this helps: This helps multiple myeloma patients looking for ways to improve their health through diet.

Plain English
This study looked at how effective immunotherapy treatments, specifically checkpoint inhibitors like pembrolizumab and ipilimumab, are for melanoma patients who also have chronic lymphocytic leukemia (CLL). Among 15 patients, 33% had a positive response to ipilimumab, but overall, there was no indication that CLL affected the treatment's effectiveness. The findings are important because they show that these therapies can still work for melanoma patients with CLL, although they might need more monitoring for serious side effects. Who this helps: This benefits melanoma patients with chronic lymphocytic leukemia and their doctors.

Plain English
This study looked at how the order in which two treatments—daratumumab and elotuzumab—are given to patients with tough-to-treat multiple myeloma affects their effectiveness. Researchers found that when daratumumab is given second, it leads to a better response rate of 64.3%, compared to just 34.8% when elotuzumab is given second. Furthermore, patients who received elotuzumab first had a significantly longer time before their disease progressed, lasting an average of 22.67 months, compared to 10.5 months for those who started with daratumumab. Who this helps: This helps patients with relapsed and refractory multiple myeloma by optimizing their treatment sequence for better outcomes.

Plain English
This study looked at the gut bacteria of 34 multiple myeloma patients to see if their composition was linked to treatment success. It found that patients who achieved minimal residual disease negativity, indicating a better response to treatment, had more of certain beneficial gut bacteria compared to those who did not. Understanding this connection is important because it could lead to new ways to improve treatment outcomes for patients. Who this helps: This helps multiple myeloma patients and their doctors.

Plain English
This study looked at a new test called the Hydrashift 2/4 Daratumumab assay, which helps doctors distinguish between a drug used to treat multiple myeloma, daratumumab, and the disease itself in patients receiving treatment. Out of 40 patients, the assay successfully identified that in 27 cases, the protein associated with the disease could be seen separately from the drug, and it confirmed ongoing disease in 11 other cases where the two proteins were initially indistinguishable. This is important because it helps doctors accurately assess a patient’s condition and their response to treatment, which can influence future care decisions. Who this helps: This helps patients with multiple myeloma and their doctors.

Plain English
This research looked at how new immune therapies, specifically immune checkpoint inhibitors like nivolumab and pembrolizumab, can treat blood cancers such as lymphoma and myeloma. The findings show that about 60-70% of patients with classical Hodgkin lymphoma respond well to these treatments, and there is promising early data for myeloma patients when these drugs are used with other therapies. This is important because it signals a shift in treatment options for these cancers, potentially improving outcomes for many patients. Who this helps: This benefits patients with lymphoma and myeloma, along with their doctors.

Plain English
This study looked at how a type of cancer treatment called PD-1 blockers works in blood cancers, particularly Hodgkin lymphoma and non-Hodgkin lymphoma. The researchers found that patients with classical Hodgkin lymphoma and certain types of non-Hodgkin lymphoma responded well to this treatment, with high response rates, but there were safety issues when combining PD-1 blockers with other drugs in multiple myeloma. Finding safe and effective combinations is important because it can lead to better treatment options for patients with these types of blood cancers. Who this helps: This helps patients with Hodgkin lymphoma, non-Hodgkin lymphoma, and multiple myeloma.

Plain English
This paper reviews new cancer treatments that help the immune system fight blood cancers, particularly focusing on drugs like pembrolizumab and nivolumab, which have shown strong responses in patients with Hodgkin lymphoma. Researchers found that blocking certain pathways in immune cells significantly improves treatment outcomes, and they discuss strategies to enhance the effectiveness of these therapies. This matters because it opens up new opportunities to help more patients with various blood cancers respond positively to treatment. Who this helps: This benefits patients with blood cancers, especially those with Hodgkin lymphoma.

Plain English
This research looks at how different imaging methods, specifically a new whole-body low-dose CT scan, can better detect bone damage caused by multiple myeloma, a type of cancer. The study finds that this new CT technique detects bone lesions more effectively than traditional X-rays, which can lead to better treatment decisions. This matters because early and accurate detection of bone disease is critical for managing multiple myeloma effectively. Who this helps: Patients with multiple myeloma and their doctors benefit from improved imaging techniques.

Plain English
This study looked at how different versions of the hepatitis C virus (HCV) manage to evade the immune system, specifically how they affect certain immune cells called CD4 T cells. Researchers found that some viral variants can prevent T cells from activating and even promote the growth of other cells that suppress immune responses, effectively weakening the body's ability to fight the virus. Understanding these mechanisms is important because it highlights how HCV can survive in patients and helps guide the development of better treatments. Who this helps: This research benefits patients with chronic hepatitis C and doctors treating them.

Plain English
This study examined how well antioxidant liposomes can protect against lung injury caused by a harmful chemical called CEES. Researchers found that using a specific antioxidant treatment significantly reduced lung damage both shortly after exposure and helped decrease inflammation. However, while some antioxidant combinations were effective immediately, others seemed to help only with longer-term lung damage, particularly one treatment that included vitamin E. Who this helps: This research benefits patients suffering from chemical-induced lung injuries.

Plain English
This study looked at how blocking a protein called C5a can help prevent heart problems caused by burn injuries. In tests with rats, researchers found that heart function dropped after burns, but when they used C5a-blocking treatment, heart function improved significantly; for example, after 24 hours, the heart issues were completely resolved. This is important because it shows a way to protect the heart in patients with severe burns, potentially improving recovery outcomes. Who this helps: This helps burn patients and their doctors.

Plain English
This study looked at the role of a type of immune cells called neutrophils during sepsis, a serious condition caused by infections. Researchers found that removing neutrophils after the onset of sepsis led to much lower levels of bacteria in the blood and improved liver and kidney function, resulting in better survival rates. Specifically, neutrophil depletion after sepsis significantly reduced harmful cytokines and improved health outcomes. However, removing these cells before sepsis made things worse, leading to higher bacteria levels and greater organ failure. Who this helps: This research benefits doctors and patients dealing with sepsis, guiding treatment strategies based on the timing of neutrophil management.